Blood-Based Lung Cancer Assay Matches CT Sensitivity in NLST Evaluation
In studies using National Lung Screening Trial biospecimens, a liquid biopsy assay showed similar sensitivity to low-dose CT screening and detected cancers missed by imaging.
In studies using National Lung Screening Trial biospecimens, a liquid biopsy assay showed similar sensitivity to low-dose CT screening and detected cancers missed by imaging.
A novel enrichment method produces virtually pure circulating tumor DNA from blood samples, showing strong sensitivity and specificity across colorectal and lung cancer patients.
University of Texas at Dallas researchers combine electrochemical biosensors with AI to identify volatile organic compounds linked to thoracic cancers.
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read MoreA case study shows how the noninvasive test detected Stage 1A mucinous adenocarcinoma in a high-risk patient whose previous tests and follow-up scans had suggested a low probability of cancer.
Read MoreNew multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.
Read MoreThe FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read MoreRoche’s VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Read MoreLung cancer screening has increased overall, but significant disparities remain, particularly among rural and underserved populations.
Read MoreScientists have developed a low-cost, fast-response sensor capable of detecting lung cancer biomarkers from a blood sample in just 40 minutes.
Read MoreA new demonstrates the high sensitivity of the NeXT Personal test for detecting ctDNA in early-stage lung cancer.
Read MoreThe ORACLE test can predict lung cancer survival at diagnosis accurately, offering new hope for tailored treatments in stage 1 patients.
Read MoreThe Nu.Q Cancer Test distinguished between malignant and benign pulmonary nodules detected by LDCT scans in suspected lung cancer.
Read MoreThe results of AI-based classifiers for lung cancer using Qlucore Insights were recently presented by researchers.
Read MoreStudies validated Biofidelity’s Aspyre Lung diagnostic tech, showcasing its ability to offer genomic profiling for actionable NSCLC variants.
Read MoreBiofidelity’s test delivers comprehensive genomic profiling for NSCLC patients from tissue or liquid biopsy samples within two days.
Read MoreRoche and Sheba Medical Center’s ARC are collaborating to enhance NSCLC diagnosis and treatment using AI-driven digital pathology tools.
Read MoreResearchers have developed a novel testing strategy for mesothelioma cancer, focusing on detecting chromosomal rearrangements in cancer DNA.
Read More